Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology company specializing in developing therapies to target RAS-addicted cancers. Their product pipeline includes RMC-4630, an SHP2 inhibitor in Phase 1/2 clinical trial for solid tumors, RMC-5845, a selective SOS1 inhibitor, RMC-5552, a hyperactivated mTORC1 signaling inhibitor, and RMC-6291 and RMC-6236, mutant-selective and RAS-selective inhibitors respectively. They also develop RAS(ON) Inhibitors targeting specific RAS variants. The company generates revenue through the research, development, and potential commercialization of these precision oncology therapies.

Products

• RMC-4630 (SHP2 inhibitor)

• RMC-5845 (SOS1 inhibitor)

• RMC-5552 (mTORC1 signaling inhibitor)

• RMC-6291 (mutant-selective RAS inhibitor)

• RMC-6236 (RAS-selective inhibitor)